Samuel Silver
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
93
Citations
4,797
Est. group size
—
Recurring co-author estimate
Active years
59
Publishing since 1968
Typically publishes in teams of ~6 · 25% small-team papers (≤3 authors) · across 14 venues
- WCN26-7011 RISK OF MAJOR ADVERSE CARDIOVASCULAR OUTCOME AMONG CHILDHOOD CANCER SURVIVORS WITH CHRONIC KIDNEY DISEASE OR HYPERTENSION
Kidney International Reports · 2026
- Real‐world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X‐linked protoporphyria
The Journal of Dermatology · 2025
- Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Zenodo (CERN European Organization for Nuclear Research) · 2024
- Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury
Zenodo (CERN European Organization for Nuclear Research) · 2024
- In Vino Veritas: An Examination of New Jersey’s Intoxication Defense
Seton Hall Journal of Legislation and Public Policy · 2024
- Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting
American Journal of Nephrology · 2024
- HTRS2023.P3.2 Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: post hoc analyses from the phase 3 ENVISION study through month 36
Research and Practice in Thrombosis and Haemostasis · 2023
- Cancer Biosimilars—A Regulatory Success So Far, but Value Still to Be Determined
JAMA Oncology · 2022
- Disease Burden and Healthcare Utilization Among Patients with Acute Intermittent Porphyria Experiencing Chronic Neuropathy: Analyses from a National Healthcare Database (1507)
Neurology · 2021
- S1105 Disease Burden and Healthcare Utilization Among Patients With Acute Intermittent Porphyria Experiencing Chronic Pain: Analyses From a National Healthcare Database
The American Journal of Gastroenterology · 2020
- S1169 Twelve-Month Interim Analysis of Efficacy and Safety of Givosiran, an Investigational RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open Label Extension
The American Journal of Gastroenterology · 2020
- S1154 Clinical Outcomes in Patients With Acute Hepatic Porphyria Treated With Givosiran Who Stopped Hemin Prophylaxis at Study Entry: A Post Hoc Analysis of Data From the Phase 3 ENVISION Study Through Month 12
The American Journal of Gastroenterology · 2020
- Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension
Blood · 2020
- Twelve-month interim analysis of efficacy and safety of givosiran, an investigational RNAi therapeutic for acute hepatic porphyria, in the envision open label extension
Journal of Hepatology · 2020
- Canons or Coin Tosses: Time-Tested Methods of Interpreting Statutory Language
Seton Hall University eRepository (Seton Hall University) · 2019
- The American Journal of Gastroenterology×5
- Seton Hall University eRepository (Seton Hall University)×3
- Cancer×2
- Journal of Hepatology×2
- Zenodo (CERN European Organization for Nuclear Research)×2
- Markus Ruetz
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Lindsay B. Michocki
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Amardeep Kumar
Biochemistry, Genetics and Molecular Biology · Indiana University
- Joseph A. Krzycki
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- E. Neil G. Marsh
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile